Addex Therapeutics Ltd Total Assets
Addex Therapeutics Ltd total assets. Based on the latest financial reports, Addex Therapeutics Ltd (ADXN) holds total assets worth CHF4.76 Million CHF (≈ $6.02 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Addex Therapeutics Ltd stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Addex Therapeutics Ltd (2006–2025)
Total assets of Addex Therapeutics Ltd from 2006 to 2025. This chart illustrates how Addex Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data. See ADXN share price today for real-time trading data and today's change.
Addex Therapeutics Ltd - Asset Composition Analysis
Addex Therapeutics Ltd Total Assets Breakdown (December 2025)
Addex Therapeutics Ltd total assets breakdown as of December 2025. Addex Therapeutics Ltd's total assets of CHF4.76 Million consist of 26.3% current assets and 73.7% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 25.8% |
| Accounts Receivable | CHF20.09K | 0.3% |
| Inventory | CHF0.00 | 0.0% |
| Property, Plant & Equipment | CHF0.00 | 0.0% |
| Intangible Assets | CHF0.00 | 0.0% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Addex Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Addex Therapeutics Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Addex Therapeutics Ltd's current assets represent 26.3% of total assets in 2025, a decrease from 91.2% in 2006.
- Cash Position: Cash and equivalents constituted 25.8% of total assets in 2025, down from 88.3% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Addex Therapeutics Ltd Competitors by Total Assets
Key competitors of Addex Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Addex Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.97 | 3.03 | 5.70 |
| Quick Ratio | 0.97 | 3.03 | 5.70 |
| Cash Ratio | 0.00 | 0.00 | 4.92 |
| Working Capital | CHF-32.56K | CHF2.14 Million | CHF17.32 Million |
Addex Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Addex Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.23 |
| Latest Market Cap to Assets Ratio | 0.61 |
| Asset Growth Rate (YoY) | -40.4% |
| Total Assets | CHF6.36 Million |
| Market Capitalization | $3.89 Million USD |
Valuation Analysis
Below Book Valuation: The market values Addex Therapeutics Ltd's assets below their book value (0.61x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Addex Therapeutics Ltd's assets decreased by 40.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Addex Therapeutics Ltd (2006–2025)
The table below shows the annual total assets of Addex Therapeutics Ltd from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF6.36 Million ≈ $8.04 Million |
-40.41% |
| 2024-12-31 | CHF10.67 Million ≈ $13.49 Million |
+129.90% |
| 2023-12-31 | CHF4.64 Million ≈ $5.87 Million |
-43.95% |
| 2022-12-31 | CHF8.28 Million ≈ $10.47 Million |
-63.26% |
| 2021-12-31 | CHF22.54 Million ≈ $28.50 Million |
+11.69% |
| 2020-12-31 | CHF20.18 Million ≈ $25.52 Million |
-38.90% |
| 2019-12-31 | CHF33.03 Million ≈ $41.76 Million |
-21.76% |
| 2018-12-31 | CHF42.21 Million ≈ $53.37 Million |
+1278.10% |
| 2017-12-31 | CHF3.06 Million ≈ $3.87 Million |
+82.02% |
| 2016-12-31 | CHF1.68 Million ≈ $2.13 Million |
-41.76% |
| 2015-12-31 | CHF2.89 Million ≈ $3.65 Million |
-27.74% |
| 2014-12-31 | CHF4.00 Million ≈ $5.06 Million |
-31.98% |
| 2013-12-31 | CHF5.88 Million ≈ $7.43 Million |
-72.95% |
| 2012-12-31 | CHF21.74 Million ≈ $27.48 Million |
-50.17% |
| 2011-12-31 | CHF43.62 Million ≈ $55.14 Million |
-41.28% |
| 2010-12-31 | CHF74.28 Million ≈ $93.92 Million |
-16.11% |
| 2009-12-31 | CHF88.55 Million ≈ $111.96 Million |
-33.08% |
| 2008-12-31 | CHF132.33 Million ≈ $167.30 Million |
-11.41% |
| 2007-12-31 | CHF149.37 Million ≈ $188.85 Million |
+222.26% |
| 2006-12-31 | CHF46.35 Million ≈ $58.60 Million |
-- |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-in… Read more